2025-01-07
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher Barrett’s Esophagus test. TissueCypher is the first AI-driven precision medicine test designed to predict a patient’s individual risk of progression from Barrett’s esophagus (BE) to esophageal cancer.